Anal Cancer in HIV Patients - Experience at Hospital de Curry Cabral
Abstract
Introduction: Men who have sex with men, particularly those infected by human immunodeficiency virus (HIV), have an increased risk of anal cancer. Unlike most opportunistic or AIDS-defining events, data have been contradictory regarding impact of antiretroviral therapy, viral suppression and immunologic reconstitution on HPV infection prevention and related cancers. Vaccination against human papillomavirus (HPV) is presently recommended in all HIV-infected patients, whereas there is still an on-going debate about the need for anal cancer screening programmes.
Material and methods: The authors performed a retrospective study of anal cancer cases diagnosed between 2000-2015 in HIV patients on follow up at the Infectious Diseases Unit at Hospital de Curry Cabral, in Lisbon. We present the clinical and epidemiological characteristics of anal cancer cases throughout a fifteen-year period.
Results: Anal cancer was diagnosed in ten patients, most of them MSM, HIV-infected for an average time of 15.1 years, with an average TCD4+ cell count of de 441 cells/uL. Anal cancer diagnosis was more frequently performed at stage III and treatment most frequently involved surgery, occasionally with radiotherapy. Four patients died.
Conclusion: There is a need for consensual anal cancer screening programs, along with a need to reinforce HPV vaccination in men, particularly men who have sex with men, regardless of HIV infection.
Downloads
References
Riedel DJ, Tang LS, Rositch AF. The Role of Viral Co-Infection in HIV-Associated Non-AIDS-Related Cancers. Curt HIV/AIDS Rep. 2015 p12:362-72.
Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015 6; 107. pii:dju503.
Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, et al. Non-AIDS defining cancers in the D:A:D Study-time trends and predictors of survival: a cohort study.BMC Infect Dis. 2013; 13:471.
Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002; 35:1127-34.
Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148:728-36.
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120-30.
Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012; 13:487-500.
Lissouba P, Van de Perre P, Auvert B. Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2013; 89:350-6.
Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS. 2012; 26:2211-22.
Brown B, Davtyan M, Galea J, Chow E, Leon S, Klausner JD. The role of human papillomavirus in human immunodeficiency virus acquisition in men who have sex with men: a review of the literature. Viruses. 2012; 4:3851-8.
Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009; 51:274-82
Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic
HPV among HIV-infected women. AIDS. 2001; 15:2157-64.
Chiao EY, Hartman CM, El-Serag HB, Giordano TP. The impact of HIV viral control on the incidence of HIV-associated anal cancer. J Acquir Immune Defic Syndr. 2013; 63:631-8.
Conley L, Bush T, Darragh TM, Palefsky JM, Unger ER, Patel P, et al. Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN Study) Investigators. Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults
in the United States. J Infect Dis. 2010; 202:1567-76.
vanVan der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HA, van Doornum GJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis.2012; 39:495-500.
de Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis. 2011; 52:1174-81.
Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008; 22:1203-11.
Smyczek P, Singh AE, Romanowski B. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013; 24:843-51.
Wilkin TJ. Screening for anal cancer: Who, when, and how. Medscape. Apr 22, 2010. [consultado em 16 Fevereiro 2014] Disponível em http://www.medscape.com/viewarticle/720388
Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The Clinical Effectiveness and Cost-effectiveness of Screening for Anal Squamous Intraepithelial Lesions in Homosexual and Bisexual HIV-Positive Men. JAMA. 1999; 281:1822-9.
Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al; CVT Vaccine Group. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011;12:862-70.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365:1576-85. doi: 10.1056/NEJMoa1010971.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3; 364(5):401-11. doi: 10.1056/NEJMoa0909537.
National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 28; 60(2):1-64. Disponível a 16 de Fevereiro de 2014 em http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm
European Aids Clinical Society. European Guidelines for treatment of HIV-infected adults in Europe. Disponível a 6 de Outubro de 2015 em http://www.eacsociety.org/files/2015_eacsguidelines_8.0-english_
revised-20151104.pdf.
Medicine Association of the Infectious Diseases Society of America. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers
for Disease Control and Prevention, the National Institutes of Health, and the HIV [consultado 10 Maio de 2015] Disponível emhttp://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf .
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
